China SXT Pharmaceuticals, Inc. Announces Plans to Increase Production
January 24 2020 - 2:23PM
Business Wire
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or
the "Company"), a specialty pharmaceutical company focusing on the
research, development, manufacturing, marketing, and sales of
Traditional Chinese Medicine Pieces ("TCMPs"), announced today that
it will be increasing its production of its entire TCM product
line, in response to recent Chinese government pronouncements
signaling a large expansion of the role and use of TCMPs in the
Chinese health care system.
The initial directive, promulgated by the State Council of the
People’s Republic of China, contained general priorities in medical
and healthcare system reform. This was followed by guidelines
issued by the State Council together with the Central Committee of
the Communist Party of China, which specifically called for all
community health service centers and township clinics in the
country to offer TCM services by 2022, including TCM-based
solutions for the prevention and treatment of, and rehabilitation
from, illness and disease. The guidelines were later reinforced
with an announcement by the State Council on October 26, 2019.
After reviewing the Chinese authorities’ guidelines, which
further directed that existing TCM hospitals should increase their
service capacity, China SXT has begun instituting plans to take
advantage of the opportunity presented through an immediate ramp up
in production of its entire TCM line, including Advanced TCMPs
(Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs,
regular TCMPs, and TCM Homologous Supplements.
Mr. Feng Zhou, Chief Executive Officer and Director of China
SXT, commented, "These new guidelines have provided us with both
the impetus and the reassurance we needed to embark on our next
phase of expansion, as we move forward to our stated goal of
becoming one of the world’s leading specialty pharmaceutical
company in TCMPs,” adding that “equally important to us is that
with the increase in production came improvements in our production
systems and technologies, which we have been able to fund thus far
through existing cashflows.”
About China SXT Pharmaceuticals, Inc.
Founded in 2005 and headquartered in Taizhou City, Jiangsu
Province, China, China SXT Pharmaceuticals, Inc. is an innovative
pharmaceutical company focusing on the research, development,
manufacture, marketing and sales of traditional Chinese medicine
pieces, which is a type of Traditional Chinese Medicine that has
been processed to be ready for use. For more information, please
visit www.sxtchina.com.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may, "will, "intend," "should," "believe," "expect," "anticipate,"
"project," "estimate" or similar expressions that do not relate
solely to historical matters, it is making forward-looking
statements. Forward-looking statements are not guarantees of future
performance and involve risks and uncertainties that may cause the
actual results to differ materially from the Company's expectations
discussed in the forward-looking statements. These statements are
subject to uncertainties and risks and for these reasons, among
others, investors are cautioned not to place undue reliance upon
any forward-looking statements in this press release. Additional
factors are discussed in the Company's filings with the U.S.
Securities and Exchange Commission, which are available for review
at www.sec.gov. The Company undertakes no obligation to publicly
revise these forward-looking statements to reflect events or
circumstances that arise after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200124005425/en/
For more information, please contact: Feng Zhou, Chief
Executive Officer Email: fzhou@sxtchina.com
China SXT Pharmaceuticals (NASDAQ:SXTC)
Historical Stock Chart
From Jan 2025 to Feb 2025
China SXT Pharmaceuticals (NASDAQ:SXTC)
Historical Stock Chart
From Feb 2024 to Feb 2025